April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Candesartan Attenuates Vascular Injury in Diabetic Retinopathy by Restoring Glyoxalase I Function
Author Affiliations & Notes
  • A. G. Miller
    Immunology, Monash University, Prahran, Australia
  • G. Tan
    Immunology, Monash University, Prahran, Australia
  • R. H. Nagaraj
    Ophthalmology, Case Western Reserve University, Cleveland, Ohio
  • M. E. Cooper
    Baker IDI, Prahran, Australia
  • J. L. Wilkinson-Berka
    Immunology, Monash University, Prahran, Australia
  • Footnotes
    Commercial Relationships  A.G. Miller, None; G. Tan, None; R.H. Nagaraj, None; M.E. Cooper, None; J.L. Wilkinson-Berka, None.
  • Footnotes
    Support  Eli Lilly New Investigator Grant
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 4806. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. G. Miller, G. Tan, R. H. Nagaraj, M. E. Cooper, J. L. Wilkinson-Berka; Candesartan Attenuates Vascular Injury in Diabetic Retinopathy by Restoring Glyoxalase I Function. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4806.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Angiotensin II (ANG II) blockade is being evaluated as a treatment for diabetic retinopathy (DR). We aimed to determine if the angiotensin type 1 receptor blocker, candesartan, improves pre-clinical DR. We investigated whether interactions between ANG II and the advanced glycation end-product pathway contributes to vascular injury in DR by reduction of glyoxalase I (GLOI).

Methods: : Bovine retinal endothelial cells (BREC) and retinal pericytes (BRP), were incubated with 100 nM ANG II for 24 hours. GLOI activity was assayed by measuring formation of S-D-lactoylglutathione. Apoptosis was evaluated by TUNEL staining. Ren-2 rats, with an enhanced renin-angiotensin system (RAS) were randomised into 3 groups: non-diabetic, streptozotocin diabetic, diabetic+candesartan (5mg/kg/day, gavage), and studied for 1, 4 and 20 weeks. Systolic blood pressure was recorded. Acellular capillaries were measured on retinal trypsin digests. Leukostasis was quantitated after rhodamine-concanavalinA perfusion. GLOI, intercellular adhesion molecule (ICAM-1), vascular endothelial growth factor (VEGF) and RAS component mRNA were quantitated by real-time PCR.

Results: : ANG II negatively influenced retinal cell survival with 3- and 4- fold increases in apoptotic BREC and BRP with ANG II treatment (P<0.05). In vivo, acellular capillaries increased in diabetic Ren-2 rats compared to control (4.66±0.56 vs 1.37±0.16/field, P<0.05) and were restored to control levels with candesartan (1.22±0.19, P<0.05). Leukostasis was increased in diabetes (249.8±59.1 vs control, 30.1±7.8/retina, P<0.01) and reduced with candesartan (29.0±5.6, P<0.05 vs diabetic). Retinal VEGF, ICAM-1 and RAS components were attenuated with candesartan. ANG II reduced GLOI mRNA (0.75±0.12 and 0.75±0.05 fold, P<0.05) and activity (83.3±5% and 83.6±3.7%, P<0.05) in BRP and BREC compared to control. In diabetic Ren-2 rats, GLOI mRNA was reduced (0.6±0.03 fold) compared to control, and restored with candesartan (1.02±0.15).

Keywords: diabetic retinopathy • apoptosis/cell death • inflammation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.